Abstract:4596 Background: Recently clinical trials like BLASST-1 and SAKK06/17 showed that immunotherapy combined with chemotherapy as neoadjuvant regimen of muscle-invasive bladder cancer (MIBC)may produce synergistic effects with good tolerability. Toripalimab, a PD-1 inhibitor, has achieved good therapeutic effects in advanced urothelial cancer. This clinical study was designed to verify the safety and efficacy of Toripalimab with gemcitabine-cisplatin (GC) as neoadjuvant therapy (NAT) for MIBC. Methods: It is a prospective, single-arm, open-label, single-center phase II clinical study from China (ChiCTR2100051298). Thirty patients with MIBC clinically staged as T2-3b N0 M0, who were scheduled for RC were enrolled. Patients received: Toripalimab 240 mg + Gemcitabine 1000 mg/m2 + Cisplatin 70mg/m2 on day 1, Gemcitabine 1000mg/m2 on day 8 every 21 days (1 cycle), totally for 4 cycles. RC will be performed 1 month after last therapy. The primary endpoint is pathological complete response (pCR), and the secondary endpoints are safety, overall survival (OS), and progression-free survival (PFS). The tumor regression effect after NAT will be evaluated by comparing the postoperative pathological results with the preoperative radiological results. The FISHER's exact test was used to analyze the relationship between genomic changes / tumor mutation burden (TMB) and pCR rate. This study has been approved by the Ethics Committee of Gulou Hospital, Nanjing. Results: From Jan 2020 to Dec 2021, 30 individuals participated in the study and received at least 1 cycle therapy, and 3 dropped out before RC. Among the patients who underwent RC, the pathological response (PaR) rate was 63% (17/27) and the pCR rate was 40.7% (11/27). The 1-year and 3-year PFS rates are 85.2% and 77.6%, respectively; The 1-year and 3-year OS rates are 96.2% and 84.6%, respectively. In the patients with PD-L1 expression ≥5% (n = 16), pCR and PaR rates was 43.8% (7/16) and 68.8% (11/16), respectively. In the patients with PD-L1 expression < 5% (n = 11), the pCR rate was 36.4% (4/11) and the PaR rate was 63.6% (7/11). The status of PD-L1 expression and TMB were not associated with pCR rate. Further biomarker analysis indicated that patients with any dual co-mutation in KMT2D/ERBB2/EPHA2 were associated with a lower pCR rate. Among the 30 patients, 24 cases (80%) experienced treatment related adverse reactions (AEs), with no grade 4 AEs nor above. Two patients experienced grade 3 AEs, including thrombocytopenia (1) and proteinuria (1). The most common AEs were pruritus (33.3%), fatigue (26.7%), and nausea (23.3%). Nine cases (30%) experienced immune-related AEs, including rash, thyroid dysfunction, increased blood glucose, and pneumonia, with no grade 3-4 AEs. Conclusions: Toripalimab combined with GC chemotherapy demonstrates good efficacy and tolerability and is an alternative option for NAT of MIBC. Clinical trial information: ChiCTR2100051298.

Effect of Patient-Derived Tumor-Like Cell Clusters on Personalized Medicine of Patients with Non-Muscle Invasive Bladder Cancer.

Microfluidic Assaying of Circulating Tumor Cells and its Correlation with Muscle Invasiveness and Tumor Grade of Urothelial Bladder Cancer

Microfluidic Assaying of Circulating Tumor Cells and Its Application in Risk Stratification of Urothelial Bladder Cancer

A Prospective Phase II Study of Neoadjuvant Therapy Guided by Personalized Drug-Testing on Patient-Derived Tumor-Like Cell Clusters for Early Breast Cancer.

Patient-derived tumor cell clusters (PTC) guiding-neoadjuvant therapy of HER2-positive breast cancer: A prospective randomized phase II clinical trial.

Patient-derived tumor-like cell clusters for drug testing in cancer therapy

A Multicenter Clinical Study: Personalized Medication for Advanced Gastrointestinal Carcinomas with the Guidance of Patient-Derived Tumor Xenograft (PDTX).

Clinical application of drug sensitive gene detection in postoperative instillation for non-muscle invasive bladder cancer

A phase II study of risk-based stratification after chemotherapy combined with PD-1 antibody: Two various bladder-sparing modalities for muscle invasive bladder cancer therapy (ReBirth).

Bladder-sparing treatment for muscle-invasive bladder carcinoma: A single-center, single-arm clinical study of sequential neoadjuvant chemotherapy followed by tislelizumab neoadjuvant immunotherapy.

Guiding adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient-derived organoids.

Real-world study of chemotherapy plus immunotherapy versus chemotherapy alone as neoadjuvant treatment guided bladder-sparing therapy for localized muscle-invasive bladder cancer.

Biomarker Exploration for neoadjuvant chemotherapy with gemcitabine combined with cisplatin in muscle-invasive bladder cancer.

Comparison of two ICI-based microtubule antagonist therapies for high-risk, non-muscle-invasive bladder cancer.

A Phase II Clinical Trial of Toripalimab Combined with Cisplatin Plus Gemcitabine Chemotherapy As Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer.

Serial Assessment Of Circulating T Lymphocyte Phenotype And Receptor Repertoire During Treatment Of Non-Muscle Invasive Bladder Cancer With Adoptive T Cell Immunotherapy

Preliminary efficacy and safety results from ReBirth: A phase II study of risk-based bladder-sparing therapy for MIBC.

Neoadjuvant gemcitabine-cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial

Efficacy and safety analysis of neoadjuvant chemotherapy combined with immunotherapy in patients with muscle-invasive bladder cancer

The different predictive value of mean platelet volume-to-lymphocyte ratio for postoperative recurrence between non-muscular invasive bladder cancer patients treated with intravesical chemotherapy and intravesical chemohyperthermia